MICVO (micvotabart pelidotin) — Topline data
Fall 2026
The Fall 2026 clinical update is expected to include analyses of the impact of dose capping on safety, tolerability, efficacy and initial durability.Source filing
PYXS biotech catalysts & pipeline
PYXIS ONCOLOGY INC · Data as of 2026-09-08
Upcoming catalysts
MICVO (micvotabart pelidotin) — Topline data
Q4 2026
We anticipate reporting updated clinical data in the fourth quarter of 2026 from the ongoing PYX-201-102 Phase 1/2 dose escalation study evaluating MICVO in combination with KEYTRUDA®, with the update focused on patients with 1L R/M HNSCC.Source filing